Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
DeepCure logo — Reimagining small molecule therapies for immune diseases

DeepCure

Reimagining small molecule therapies for immune diseases

Founded 2018 United States Boston, United States 28 employees Series A Total: $64.60M AI, Biotechnology +1

General Information

Company Name DeepCure
Founded Year 2018
Location United States Boston, United States
Employees 28
Industries AI, Biotechnology, Machine Learning
Funding Stage Series A
Business Model B2B, B2B2C
Revenue Model Licensing, Performance Based, Value Based Pricing
Social

BounceWatch is an independent company data service, not affiliated with DeepCure. To contact DeepCure, visit deepcure.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DeepCure compare?

A PDF of DeepCure and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DeepCure soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DeepCure

DeepCure, founded in 2018 and headquartered in the United States, is innovating the landscape of small molecule therapies specifically targeting immune and inflammatory diseases. The company's slogan, "Reimagining small molecule therapies for immune diseases," encapsulates its mission to introduce groundbreaking solutions in this vital sector.

DeepCure employs a cutting-edge chemistry platform, integrating AI with advanced physics-based tools to discover novel molecules. Currently, their pipeline features an oral STAT6 program with multiple novel scaffolds and an oral BRD4(BD2) program, noted for its selectivity in inhibition. Clinical trials are set to commence by 2026, highlighting a robust timeline for development.

In terms of financial traction, DeepCure secured a $24.60M Series A investment on 01 April 2024, led by IAG Capital Partners, underscoring strong investor confidence in their disruptive approach within the AI, Biotechnology, and Machine Learning industries.

Taxonomy: Small Molecule Therapies, Immune Diseases, Inflammatory Diseases, AI-Driven Drug Discovery, Novel Molecules, Drug Discovery Platform, Oral STAT6 Program, Selective Inhibitors, BRD4(BD2) Program, Precision Therapeutics, Unmet Medical Needs, Chemistry Innovation, Advanced Physics Tools, Immunology Solutions, Pharmaceutical Development

Services & Products

Development of small molecule therapies
Research and development of STAT6 inhibitors
Collaboration with academic and research institutions

Target Customers

Pharmaceutical companies Biotech firms Healthcare providers Medical researchers Patients with immune diseases

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $24.60M 1
IAG Capital Partners
IAG Capital Partners
01 Apr 2024
Series A $40.00M 4
Sapir Venture Partners TLV Partners
Sapir Venture Partners, TLV Partners +2
01 Nov 2021
Round Undisclosed -
01 Apr 2020
Seed Undisclosed 2
Creative Destruction Lab Sapir Venture Partners
Creative Destruction Lab, Sapir Venture Partners
01 Dec 2018
Spinout Undisclosed 1
Massachusetts Institute of Technology
01 Sep 2018

DeepCure Alternatives & Competitors

View All Alternatives
DeepCure vs
Integrated Biosciences, Inc.
Integrated Biosciences, Inc. United States

Unravelling complex biology with optogenetics, chemistry and computation for small molecule discover...

Seed
18 employees
Biopharma, Biotechnology
DeepCure vs
Empress Therapeutics
Empress Therapeutics United States

Medicines from within

Venture round
16 employees
AI, Biotechnology
DeepCure vs
Aria Pharmaceuticals
Aria Pharmaceuticals United States

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel...

Series B
4 employees
AI, Big Data
View all alternatives

FAQ About DeepCure

Reimagining small molecule therapies for immune diseases
DeepCure was founded in 2018.
DeepCure is headquartered in Boston, United States.
DeepCure operates in AI, Biotechnology and Machine Learning. Its work centres on Small Molecule Therapies, Immune Diseases, Inflammatory Diseases and AI-Driven Drug Discovery. Its customers include Pharmaceutical companies, Biotech firms and Healthcare providers.
DeepCure has a B2B and B2B2C business model. Its revenue comes from Licensing, Performance Based and Value Based Pricing.
DeepCure has approximately 28 employees.
DeepCure has completed 5 funding rounds, raising a total of $64.60M. The latest funding stage is Series A.
DeepCure offers: Development of small molecule therapies, Research and development of STAT6 inhibitors, Collaboration with academic and research institutions.
Top alternatives and competitors to DeepCure include Integrated Biosciences, Inc., Empress Therapeutics, Aria Pharmaceuticals, 1910 Genetics, Silexon AI. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DeepCure and Integrated Biosciences, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DeepCure, https://bouncewatch.com/company/deepcure, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes